Castle Biosciences Inc Overview
Pro stress-test →Castle Biosciences is a molecular diagnostics company that provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The company leverages gene expression profiling and spatialomics technologies to deliver personalized, clinically actionable molecular tests that guide treatment decisions for patients and clinicians.
Strategic Profile
Pro stress-test →In 2025, Castle achieved total test reports for core revenue drivers (DecisionDx-Melanoma and TissueCypher) increasing 37% over 2024, and exceeded full-year revenue guidance at $344 million. The company maintains strong analyst sentiment with an average "Strong Buy" rating and a 12-month stock price target of $47.17, representing an 84.55% upside from current levels.
Competitive Landscape
Pro stress-test →Castle competes in the precision oncology diagnostics and molecular testing space against companies like Guardant Health (liquid biopsies for cancer), Myriad Genetics (genetic testing and oncology diagnostics), and Exact Sciences (cancer screening and diagnostics). Castle's differentiation lies in its focus on solid tumor risk stratification, spatialomics technology (TissueCypher), and expansion into adjacent high-value clinical areas like Barrett's esophagus management.
Industry Context
Castle Biosciences Inc operates in Molecular Diagnostics & Precision Oncology.
Key facts
Founded: 2007 · Headquarters: Friendswood, Texas, US · Employees: 761 · Revenue: $344M (2025) · Market cap: $879.2M